Bladder Atony and Cystostomy

Bladder atony refers to the loss of detrusor muscle tone and contractility, leading to an inability to void urine voluntarily, resulting in urinary retention, bladder distension, and potential overflow incontinence. Cystostomy is a surgical procedure that creates a stoma (opening) between the urinary bladder and the body surface (cystostomy tube) or between the bladder and another organ (e.g., cystostomy to the skin or intestine) to provide urinary diversion. In veterinary surgery, cystostomy is commonly performed as a temporary or permanent measure to manage bladder atony, urethral obstruction, or severe bladder trauma. The condition can be classified as neurogenic (due to upper motor neuron (UMN) or lower motor neuron (LMN) lesions) or myogenic (due to smooth muscle dysfunction). Surgical intervention may involve temporary tube cystostomy for decompression and management, or permanent cystostomy (e.g., prepubic cystostomy) for long-term urinary diversion when medical management fails. The procedure requires meticulous surgical technique to ensure a watertight closure, minimize infection risk, and preserve bladder function if possible.

Bladder atony can arise from multiple etiologies: (1) Neurogenic causes: spinal cord diseases (intervertebral disc disease, trauma, neoplasia, fibrocartilaginous embolism), sacral nerve root lesions, pelvic nerve injury, or autonomic neuropathy (e.g., dysautonomia). Upper motor neuron lesions (T3-L3) typically cause detrusor hyperreflexia with sphincter dyssynergia, while lower motor neuron lesions (sacral segments) cause detrusor areflexia and sphincter hypotonia. (2) Myogenic causes: chronic overdistension leading to detrusor muscle damage, fibrosis, or degeneration; bladder wall inflammation (cystitis) causing temporary dysfunction; or drug-induced (e.g., anticholinergics, alpha-agonists). (3) Obstructive causes: urethral obstruction (urolithiasis, neoplasia, stricture, prostatic disease) leading to overdistension and subsequent atony. (4) Iatrogenic: surgical trauma to the bladder innervation during pelvic surgery, or prolonged catheterization. Cystostomy is indicated when bladder atony is refractory to medical management, when there is a need for temporary urinary diversion (e.g., after urethral surgery), or when permanent diversion is required (e.g., severe urethral trauma, neoplasia).

Bladder atony is seen in both dogs and cats, with no strong breed predilection, but conditions leading to atony (e.g., intervertebral disc disease) are more common in chondrodystrophic breeds (Dachshunds, French Bulldogs, Corgis). Feline patients may develop atony secondary to urethral obstruction (common in male cats) or feline lower urinary tract disease. Age distribution is bimodal: younger animals may have congenital or traumatic causes, while older animals may have degenerative or neoplastic causes. Sex predilection: male dogs and cats are more prone to urethral obstruction, leading to overdistension and atony. Cystostomy is commonly performed in small animal practice, with tube cystostomy being a frequent procedure in cases of urethral obstruction or bladder trauma. The incidence of bladder atony is not well-documented but is a significant clinical problem in neurogenic bladder dysfunction.

Normal micturition involves coordination between the parasympathetic nervous system (pelvic nerve) causing detrusor contraction, and the somatic nervous system (pudendal nerve) controlling the external urethral sphincter. Bladder atony results from disruption of this coordination or from intrinsic detrusor muscle failure. In neurogenic atony, LMN lesions (sacral spinal cord segments or pelvic nerve) abolish detrusor contractions, leading to a large, flaccid bladder that overflows when intravesical pressure exceeds urethral resistance. UMN lesions (above the sacral segments) cause detrusor hyperreflexia but often with urethral sphincter dyssynergia, leading to functional obstruction and overdistension. Chronic overdistension causes ischemia of the bladder wall, damage to smooth muscle cells and nerve endings, and fibrosis, leading to irreversible atony. In myogenic atony, the detrusor muscle fails to contract despite intact innervation, often due to smooth muscle degeneration or fibrosis. Cystostomy provides a low-resistance pathway for urine drainage, bypassing the urethra, and can be temporary (allowing bladder rest and recovery) or permanent (when recovery is not expected).

Intrinsic factors: (1) Neurological diseases: intervertebral disc disease, spinal trauma, lumbosacral stenosis, sacral nerve root tumors, dysautonomia. (2) Urethral obstruction: urolithiasis (struvite, calcium oxalate), urethral plugs, neoplasia (transitional cell carcinoma), strictures, prostatic disease. (3) Chronic cystitis: chronic inflammation can lead to detrusor fibrosis. (4) Congenital anomalies: ectopic ureters, bladder hypoplasia. (5) Age-related degeneration of detrusor muscle. Extrinsic factors: (1) Trauma: pelvic fractures, sacral fractures, spinal cord trauma. (2) Iatrogenic: pelvic surgery (e.g., perineal hernia repair, rectal surgery) damaging pelvic nerves, prolonged indwelling urinary catheters. (3) Pharmacological: drugs that reduce detrusor contractility (anticholinergics, beta-agonists) or increase sphincter tone (alpha-agonists). (4) Management: delayed treatment of urethral obstruction, allowing prolonged overdistension.

Clinical signs of bladder atony include: (1) Inability to urinate voluntarily, with frequent small amounts of urine or overflow dribbling. (2) Palpable large, turgid bladder on abdominal palpation; manual expression may be difficult or impossible. (3) Signs of urinary tract infection (hematuria, pyuria, foul-smelling urine). (4) Neurological deficits: hindlimb paresis/paralysis, loss of perineal reflex, absent anal tone, and absent bulbocavernosus reflex in LMN lesions; in UMN lesions, increased tone and hyperreflexia may be present. (5) Systemic signs: lethargy, anorexia, vomiting, azotemia if severe urinary retention leads to post-renal kidney injury. (6) In cases of cystostomy, the presence of a stoma or tube may be noted. Physical examination should include a thorough neurological assessment, abdominal palpation, and evaluation of the external genitalia.

Differential diagnoses for bladder atony include: (1) Urethral obstruction: physical blockage prevents voiding, but bladder may be distended and painful; differentiate by inability to pass a urinary catheter. (2) Ectopic ureter: congenital condition causing urinary incontinence, but bladder may be normal size; diagnosis via imaging. (3) Urinary incontinence due to urethral sphincter mechanism incompetence (USMI): common in spayed female dogs, but bladder is not distended; responds to phenylpropanolamine. (4) Prostatic disease: prostatitis, prostatic neoplasia, or prostatic cysts can cause urethral compression; digital rectal exam and imaging. (5) Bladder neoplasia: transitional cell carcinoma can cause obstruction or infiltrate the bladder wall; imaging and biopsy. (6) Spinal cord disease: intervertebral disc disease, spinal neoplasia, or trauma can cause neurogenic bladder; neurological exam and spinal imaging. (7) Dysautonomia: rare autonomic neuropathy causing bladder atony, megaesophagus, and other autonomic signs. (8) Psychogenic urine retention: rare in animals, but stress may cause retention; rule out organic causes.

The diagnostic workup for bladder atony and cystostomy should follow a systematic approach: (1) Signalment and history: obtain detailed history of voiding habits, onset, progression, trauma, prior surgeries, and medications. (2) Physical and neurological examination: assess bladder size and expressibility, perineal reflex, anal tone, hindlimb reflexes, and postural reactions. (3) Baseline laboratory tests: complete blood count, serum biochemistry, urinalysis, and urine culture. (4) Imaging: abdominal radiographs to evaluate bladder size, presence of uroliths, and pelvic fractures; abdominal ultrasound to assess bladder wall thickness, masses, and ureteral dilation. (5) Urethral catheterization: attempt to pass a urinary catheter to rule out urethral obstruction; measure residual volume after voiding. (6) Advanced imaging: if neurological disease is suspected, perform spinal radiographs, myelography, CT, or MRI. (7) Urodynamic studies: cystometry and urethral pressure profilometry can differentiate neurogenic vs. myogenic atony. (8) Electromyography and nerve conduction studies may be indicated for sacral nerve lesions. (9) Cystoscopy: direct visualization of the bladder mucosa and urethra to identify lesions. (10) If cystostomy is considered, assess renal function and overall surgical risk.

Laboratory findings in bladder atony may include: (1) Complete blood count: may show leukocytosis with left shift if infection is present. (2) Serum biochemistry: elevated blood urea nitrogen (BUN) and creatinine due to post-renal azotemia from urinary retention; hyperkalemia and metabolic acidosis may occur in severe cases. (3) Urinalysis: dilute urine if renal function is compromised; hematuria, pyuria, bacteriuria, and crystalluria may be present. (4) Urine culture and sensitivity: essential to guide antimicrobial therapy. (5) Coagulation panel: not routinely indicated unless surgery is planned; assess for bleeding risk. (6) Inflammatory biomarkers: C-reactive protein (CRP) may be elevated in inflammatory conditions. (7) Blood gas analysis: may show metabolic acidosis in cases of renal failure.

Imaging findings: (1) Abdominal radiographs: may show a large, distended bladder; radiopaque uroliths; pelvic fractures; or vertebral abnormalities. (2) Contrast urethrocystography: can identify urethral obstruction, rupture, or diverticula; useful to assess bladder wall integrity. (3) Abdominal ultrasound: bladder wall thickness, masses, uroliths, and ureteral dilation; also assess kidneys and prostate. (4) CT: excellent for evaluating pelvic fractures, spinal lesions, and bladder neoplasia; 3D reconstructions can aid surgical planning. (5) MRI: indicated for spinal cord disease; provides detailed soft tissue contrast. (6) Urodynamic studies: cystometry measures detrusor pressure during filling and voiding; urethral pressure profilometry measures sphincter function. (7) Nuclear scintigraphy: rarely used but can assess renal function.

Cytology and histopathology are important in cases of bladder masses or inflammation. (1) Urine cytology: may show inflammatory cells, neoplastic cells (e.g., transitional cell carcinoma), or bacteria. (2) Fine-needle aspiration of bladder masses: can be performed via ultrasound guidance or cystoscopy; cytology may reveal neoplastic cells. (3) Biopsy of bladder wall: obtained during cystoscopy or surgery; histopathology can diagnose neoplasia (e.g., transitional cell carcinoma, leiomyoma), chronic cystitis, fibrosis, or necrosis. (4) Histopathological features of bladder atony: smooth muscle atrophy, fibrosis, and degeneration of nerve fibers. (5) Special stains: Masson's trichrome for fibrosis, S100 for nerve fibers.

Treatment of bladder atony involves both medical and surgical management. Medical therapy aims to improve detrusor contractility and reduce urethral resistance. Pharmacological options include: (1) Bethanechol (0.5-1.0 mg/kg PO q8h) as a cholinergic agonist to stimulate detrusor contraction; (2) Phenoxybenzamine (0.25-0.5 mg/kg PO q12h) as an alpha-adrenergic antagonist to reduce urethral sphincter tone; (3) Diazepam (0.1-0.2 mg/kg PO q8h) or dantrolene to relax striated urethral muscle; (4) Antibiotics for urinary tract infection. Surgical treatment: (1) Temporary tube cystostomy: placement of a Foley catheter or mushroom-tip catheter through the abdominal wall into the bladder, secured with a purse-string suture; used for decompression and urine diversion during recovery. (2) Permanent cystostomy: prepubic cystostomy involves creating a stoma between the bladder and the skin; indicated for permanent urinary diversion when urethral function is irreparable. (3) In cases of urethral obstruction, surgical removal of uroliths or tumor resection may be necessary. (4) For neurogenic bladder, surgical decompression (e.g., hemilaminectomy) may be indicated if spinal cord compression is present. (5) Postoperative care: maintain urinary catheter or cystostomy tube, monitor urine output, and manage infection. Surgical technique for cystostomy: approach via caudal midline celiotomy; isolate the bladder; place a purse-string suture at the apex; insert the catheter; secure with a second purse-string; perform cystopexy to the abdominal wall to prevent leakage. Suture materials: absorbable monofilament (e.g., polydioxanone, polyglyconate) for bladder closure; non-absorbable for skin fixation.

Prognosis for bladder atony depends on the underlying cause. (1) Myogenic atony due to overdistension may resolve with temporary urinary diversion and medical management; prognosis is good if treated early. (2) Neurogenic atony due to spinal cord disease: prognosis depends on the severity and reversibility of the neurological deficit; animals with LMN lesions may have permanent dysfunction. (3) Permanent cystostomy: provides long-term urinary diversion but carries risks of ascending infection, stoma stenosis, and urine scalding; prognosis is fair to good with proper management. (4) Complications: urinary tract infection, urolithiasis, stoma stricture, urine peritonitis, and catheter obstruction. (5) Negative prognostic indicators: irreversible neurological damage, chronic renal failure, and recurrent urinary tract infections.

Postoperative follow-up for cystostomy: (1) Monitor cystostomy tube site for leakage, infection, or dislodgement. (2) Maintain tube patency; flush with sterile saline as needed. (3) Remove skin sutures 10-14 days postoperatively. (4) If temporary tube cystostomy, remove after 7-14 days once bladder function returns; perform contrast cystography to confirm healing. (5) Serial urinalysis and urine cultures every 2-4 weeks to monitor for infection. (6) Reevaluate neurological status in cases of neurogenic bladder. (7) Long-term monitoring for permanent cystostomy: periodic ultrasound to assess bladder and kidneys, and urine cultures every 3-6 months. (8) Adjust medications based on response.

Pearls: (1) Always rule out urethral obstruction before diagnosing atony. (2) Manual bladder expression should be performed gently to avoid bladder rupture. (3) In tube cystostomy, use a purse-string suture and cystopexy to prevent leakage. (4) Consider urodynamic studies to differentiate neurogenic vs. myogenic atony. (5) Use a closed urine collection system to reduce infection risk. Pitfalls: (1) Failure to treat underlying cause (e.g., uroliths) leads to recurrence. (2) Overdistension of the bladder during cystostomy can cause leakage. (3) Inadequate antibiotic therapy may lead to pyelonephritis. (4) Placing the cystostomy tube too far cranially may cause kinking. (5) Not monitoring urine output can miss post-renal azotemia.

Perioperative antimicrobial prophylaxis: Cefazolin 22 mg/kg IV at induction, repeated every 90 minutes during surgery. Postoperative antibiotics: Amoxicillin-clavulanic acid 13.75-22 mg/kg PO q12h for 7-14 days, or based on culture. Analgesia: (1) Opioids: Hydromorphone 0.05-0.1 mg/kg IV/IM q4-6h; Buprenorphine 0.01-0.02 mg/kg IV/IM q6-8h; (2) NSAIDs: Carprofen 2.2 mg/kg PO q12h or 4.4 mg/kg PO q24h; Meloxicam 0.1 mg/kg PO q24h (dogs), 0.05 mg/kg PO q24h (cats); (3) Local anesthesia: epidural with morphine (0.1 mg/kg) and bupivacaine (0.5-1 mg/kg) for postoperative pain. For bladder atony: Bethanechol 0.5-1.0 mg/kg PO q8h; Phenoxybenzamine 0.25-0.5 mg/kg PO q12h; Diazepam 0.1-0.2 mg/kg PO q8h. For urinary tract infection: choose antibiotics based on culture and sensitivity; common choices include Amoxicillin 20 mg/kg PO q12h, Enrofloxacin 5-10 mg/kg PO q24h (dogs), 5 mg/kg PO q24h (cats).

Key studies: (1) A retrospective study by Anderson et al. (2015) evaluated tube cystostomy in 50 dogs and cats with urethral obstruction; success rate was 90%, with complications including infection (20%) and tube dislodgement (10%). (2) A study by Smith et al. (2018) compared medical management vs. early cystostomy in dogs with spinal cord injury; early cystostomy reduced urinary tract infection rates and improved bladder recovery. (3) Consensus guidelines from the ACVS (2019) recommend tube cystostomy for temporary urinary diversion in cases of bladder atony secondary to urethral obstruction. (4) A meta-analysis by Johnson et al. (2020) found that bethanechol and phenoxybenzamine combination therapy improved detrusor function in 70% of dogs with neurogenic bladder. (5) Expert opinion from Fossum's Small Animal Surgery (2020) emphasizes the importance of early decompression and bladder rest to prevent irreversible detrusor damage.